Product
Supplier
Encyclopedia
Inquiry
Tirzepatide (API) buy - large image1
Tirzepatide (API) buy - image1
Tirzepatide (API) buy - image2
Tirzepatide (API) buy - image3
Tirzepatide (API) buy - image4

Tirzepatide (API)

TDS 1112 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Hangzhou

Packaging:

1g;50g 100g

Sample Available:

Yes

Price valid (until):

2026-05-08

Company Type:
Manufactory
Location:
China
Payment Terms:
TT against copy of documents
Average Lead Time:
7 days
Qualification:
Main Products:

Semaglutide,Retatrutide,Tirzepatide,Linaclotide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description

    Product Name:Tirzepatide peptide API

    CAS NO:2023788-19-2

    Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

    Molecular Weight: ~4813.5

    Purity: ≥99% (by HPLC)

    Appearance: White  powder

    Grade: Pharmaceutical Grade / API Grade

    Shelf Life: 24 months

    Storage Condition: 2-8°C, protected from light, sealed storage

    Packaging: 1g/bag, 5g/bag, 10g/bag, 100g/bag, or as customer's request

    US DMF Status: #039900 (Active)

    GMP Compliance: Manufactured under cGMP standards

    Product Usage

    Tirzepatide is a first-in-class dual agonist targeting the human GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is a synthetic 39-amino acid linear peptide conjugated to a C20 fatty diacid moiety, which enables high albumin binding and a prolonged half-life.

    Tirzepatide uniquely combines the effects of both GIP and GLP-1 to enhance glucose-dependent insulin secretion while reducing appetite and food intake. It represents the next generation of incretin-based therapies beyond single agonists.

    Clinical studies have demonstrated that tirzepatide significantly improves glycemic control and achieves substantial weight reduction. In Phase 3 clinical trials, patients taking tirzepatide experienced an average weight loss of 15-21% depending on the dose, with significant improvements in cardiometabolic risk factors.

    Key Benefits:

    • Dual GIP and GLP-1 receptor activation

    • Once-weekly administration

    • Significant HbA1c reduction (1.5-2.0%)

    • Substantial weight loss (15-21% at higher doses)

    • Improvements in blood pressure and lipid profile

    How much weight can you expect to lose with tirzepatide?

    Clinical trials have shown that patients taking tirzepatide achieved an average weight reduction of 15-21% over 72 weeks, depending on the dose, with the 15 mg dose showing the greatest efficacy.


    FAQ

    1. May I get a sample before placing an order?

    Yes, samples are available. For regular products, samples are free of charge and you only need to bear the freight. For high-value products, you need to pay for the freight and a certain product cost. When we cooperate for some time or when you become our VIP customer, free samples will be offered when needed.

    2. Which payment methods are available for your company?

    T/T, PayPal, bank transfer, and other options. You can choose the one that is most convenient for you.

    3. How and when can I get my goods after payment?

    For small quantities, products will be delivered by international courier (DHL, FedEx, TNT, etc.) or by air. Usually, it takes 5-7 days to receive the goods after shipment. For large quantities, shipping by sea is more cost-effective. It takes 15-30 days to reach your destination port, depending on the port location.

    4. Is it possible to use my own label or packaging?

    Yes. If needed, we can accommodate custom labeling and packaging requirements. Please provide your specifications and we will confirm feasibility.

    5. What is the purity and quality standard of your Tirzepatide API?

    Our Tirzepatide API is manufactured under cGMP standards with purity ≥98% by HPLC. Higher purity (≥99%) is available upon request. We provide comprehensive documentation including COA, stability data, and DMF filing support.

    6. What is the recommended storage condition?

    Store at -20°C for long-term storage, or 4°C for up to 2 years. Protect from light and keep dry. The shelf life is 24 months under recommended storage conditions.

    7. Do you provide regulatory support for filing?

    Yes, we provide regulatory support including DMF filing assistance, documentation packages, and technical support for customer submissions.


    Company Profile

    Hangzhou ThinHeal Pharma-Tech Co., Ltd. (ThinHeal) is a high-tech enterprise specializing in the research, development, production, and sales of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience, positioning the company at the forefront of the industry.

    The company has a complete and efficient peptide R&D, production, and sales system, and provides a full range of peptide industrialization services, including:

    • Peptide API R&D and production business

    • Peptide customized R&D and production (CDMO) business

    • Beauty peptide research, development, and production business

    The company's revenue is mainly derived from peptide API sales and CDMO services. The company has successfully completed US FDA DMF filings for multiple products. The CDMO business includes project-based entrusted research and development, entrusted production, and sales. The main customers of the CDMO business are innovative drug companies and scientific research institutions, among which some pharmaceutical companies have cooperated with ThinHeal since the product development stage and have established solid cooperative relationships.

    ThinHeal is committed to providing high-quality peptide APIs and comprehensive technical support to customers worldwide, with a focus on regulatory compliance, supply chain reliability, and customer satisfaction.


    Contact Us

    For pricing, DMF status, sample requests, or technical inquiries regarding Tirzepatide API, please contact our sales team.


    Shop Tirzepatide (API)-Detailed Image 1
    Shop Tirzepatide (API)-Detailed Image 2
    Shop Tirzepatide (API)-Detailed Image 3
    Shop Tirzepatide (API)-Detailed Image 4
    Shop Tirzepatide (API)-Detailed Image 5
    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Certificates
    • Tirzepatide (API) Certificates 1 TDS

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Categories:

    Polypeptide

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Semaglutide,Retatrutide,Tirzepatide,Linaclotide

    Location:

    8th Floor, Building 2, Phase 5, Xiasha Heda Pharmaceutical Valley, Qiantang District, Hangzhou, Zhejiang Province

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    7 days

    Total Annual Revenue:

    $25 million-$50 million

    Total Employees:

    301-500

    Year of Establishment:

    2019

    Company Certificates
    • Hangzhou Thinheal PharmaWC WC
    • Hangzhou Thinheal PharmaGMP GMP

    杭州信海医药科技有限公司成立于2019年,是一家专注于多肽产品的研发、生产、销售与定制、研发生产相结合的生物医药企业。核心管理团

    队由具有深厚医药专业背景的专业人士组成。信海医药建有一个研发中心和两个生产基地,目前化学合成多肽总产能已达数吨级规模。


         公司具备完整高效的多肽研发、生产及销售体系,提供全方位的多肽产业化服务,包括原料药研发和生产业务、制剂研发业务、多肽定制研发生产(CDMO)业务、以及美容肽研发生产业务。现阶段产品主要包括司美格鲁肽、替尔泊肽、利那洛肽、瑞塔鲁肽等数十个品种,其中司美格鲁肽、替尔泊肽、利那洛肽等多个品种已完成美国FDA DMF备案。

         公司以固、液相结合的化学合成工艺手段为驱动,建有复杂多肽及类肽化学合成及修饰平台、多肽片段设计与合成技术平台、多分离手段纯化平台等完善研发体系,拥有一支130人以上研发队伍,博士、硕士学历人员占比近20%,核心研发团队拥有超过20年的多肽药物开发经验,具备深厚的专业背景和丰富的实践经验.

  • Inquiry History
    1112 Inquiries
    Country Product Purchase Quantity Date Posted
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 19, 2026
    Philippines

    tirzepatide

    40 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    Tirzepatide

    300 MG Oct 19, 2026
    Philippines

    Tirzepatide

    10 PCS Oct 16, 2026
    United Kingdom

    Tirzepatide

    1 MT Oct 16, 2026
    United States

    Tirzepatide 30

    1 MT Oct 16, 2026
    United States

    Tirzepatide

    2.5  Oct 13, 2026
    United Kingdom

    Tirzepatide

    20 MG Oct 12, 2026
    Netherlands

    Tirzepatide

    10 MT Oct 12, 2026
    United States

    Tirzepatide

    30 MG Oct 10, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.